NCT07215390View on ClinicalTrials.gov

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

November 30, 2027

Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
DRUG

APL-3007, pegcetacoplan (APL-2)

Complement C3 inhibitor

DRUG

APL-3007, pegcetacoplan (APL-2)

Complement C3 Inhibitor

OTHER

Placebo, Syfovre

Complement C3 Inhibitor

Trial Locations (2)

21740

RECRUITING

Cumberland Valley Retina Consultants (CVRC), Hagerstown

94598

RECRUITING

Bay Area Retina Associates - Walnut Creek, Walnut Creek

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY

NCT07215390 - A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | Biotech Hunter | Biotech Hunter